A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
Pooled analyses from 2 clinical trials show that voclosporin, a novel calcineurin inhibitor, is safe and effective in managing lupus nephritis.
Early data from a small ongoing trial shows that pegloticase, which is administered by injection, can result in substantial and sustained decreases in serum uric acid in kidney transplant recipients with treatment-refractory gout.
Patients with systematic lupus erythematosus who have a low platelet distribution width are more likely to have lupus nephritis.
Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone.
